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Background: This pilot study, conducted on a 1/97th representative sample of French claims data, prepared a
project to assess the effectiveness of Montelukast (MTL-4) as add-on therapy for asthma in infants (6–24 months)
compared to inhaled corticosteroids (ICS), based on real-world data. Due to the very recent opening of French
claims data for effectiveness research, and the complex structure of this data source, we first tested the feasibility of
identifying infants with asthma and outcome criteria, and the ability to perform relevant comparisons.
Methods: We identified a cohort of infants with uncontrolled asthma and receiving ≥2 consecutive dispensations
of any respiratory drug (R03 ATC classification) during a 6-month period. Uncontrolled asthma was identified either
from exacerbations or from markers of acute loss of asthma control; date of occurrence of an event (exacerbation
and/or acute loss of asthma control) was defined as index date. The study groups comprised infants receiving MTL-4 +/−
ICS (MTL-4 group) or ICS without MTL-4 (ICS group) at index date. These two groups were matched on gender, age,
quarter of index date, therapy before index date, past asthma-related hospitalization (ever), and were followed for
6 months. The outcome was the rate of infants with uncontrolled asthma, defined as above.
Results: This pilot cohort study included 1,149 infants with asthma (mean age 14.1 months, 64% boys). Of these, 51
and 768 were assigned to the MTL-4 and ICS groups, respectively. Uncontrolled asthma occurred in 78.8% and 78.4% of
infants in these groups, respectively (oral corticosteroids were dispensed to 49% and 61%, respectively). Assessment of
uncontrolled asthma, exposure to MTL-4 and ICS, and occurrence of outcomes were achieved. For the development of
matching criteria, we defined a new marker of severity (therapeutic typologies).
Conclusion: These data support the feasibility of the final project, to be conducted on claims data from the whole
French population. We also showed that, with appropriate methodology and by using valid criteria, French claims data
are an adequate resource for conducting comparative effectiveness studies in pediatric asthma. Finally, the algorithm
used to identify infants with asthma could be applied to other studies using claims data.
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Asthma is a common disease in childhood. In the European
Union, it was estimated that 7% of children and adolescents
have self-reported asthma and 12% wheezing [1]. Mon-
telukast 4 mg (MTL-4) is an add-on therapy for young
asthmatic children. MTL-4 was approved in March
2010 for use in children aged 6 months to 5 years with
mild to moderate persistent asthma, insufficiently con-
trolled with inhaled corticosteroids potentially associated
with short acting beta agonists [2].
Regular therapy with inhaled corticosteroids (ICS) or
leukotriene-receptor antagonists (LTRA) is effective in
reducing asthma exacerbations in adults and children
[3-6]. International guidelines recommend ICS as pre-
ferred controller medication in children with asthma,
with LTRA as an alternative option [7-10]. This recom-
mendation was based on a 2004 Cochrane Review of 27
trials including adults or children that reported a 65%
higher risk of exacerbations requiring systemic steroids in
patients treated with LTRA compared to those treated with
ICS [11]. These trials entailed rigorous drug prescribing
and closely monitored subjects, resulting in more regular
drug use than is observed in clinical practice. In contrast,
drug claims studies have revealed that similar or better
health outcomes were obtained with LTRA compared to
ICS, raising uncertainty as to the relative effectiveness of
ICS versus LTRA in real-life practice [12,13].
Pharmacoepidemiological studies using administrative
healthcare databases are a powerful means of assessing
drug use and effects in clinical practice. National French
claims data (Système National d’Information Inter-Régimes
de l’Assurance Maladie, SNIIR-AM) record exhaustive
reimbursed medical resource utilization, including related
costs, for the overwhelming majority of the French popula-
tion, i.e. 86% of 65.4 million people. However, due to the re-
cent opening of SNIIR-AM data for effectiveness research,
and the complex structure of this resource, the feasibility of
our final project (which is to compare the effectiveness of
MTL-4 vs. ICS on health outcomes of infants with mild to
moderate uncontrolled asthma) was first tested here using
a 1/97th sample of the full data set (Echantillon Généraliste
de Bénéficiaires, EGB) [14].
The questions addressed by the EGB feasibility study
included the identification of infants with asthma and
the extent of MTL-4 and ICS use (to assess the statis-
tical power for group comparison). We also verified the
occurrence of outcomes (acute loss of asthma control
and exacerbations) and the feasibility of matching ac-
cording to predefined criteria.
Methods
Data source
SNIIR-AM records exhaustive medical resource utilization
of the population covered by the national health insurancescheme, including hospital activity and expenditure data
(Programme Médicalisé des Systèmes d’Information, PMSI).
The EGB is a 1/97th representative random sample of the
SNIIR-AM. It includes information on long-term disease
status (LTD status) that allows severe patients to receive
therapy without advancing payment. The EGB also contains
information on free-access-to-care status (CMU-C) that en-
ables patients of low socioeconomic status to receive free
medical care. In the absence of diagnoses (except for hospi-
talizations or LTD status), French claims data usually require
the use of proxies to identify asthma and outcomes criteria.
This observational study was conducted on anon-
ymized claims data, and the National Informatics and
Liberty Committee has delivered an overall authorization
to use EGB data for research purposes. This study has
been performed with the approval of the French institute
of health data (Institut des Données de Santé, approbation
n°37, February 1, 2012).
Study design
Using EGB data, we constructed a prospective cohort of
infants with asthma; two groups were identified, one treated
with ICS (beclomethasone, fluticasone, or budesonide)
without MTL-4, and the other with MTL-4 with or without
ICS (Figure 1). In the French Guidelines [2], MTL-4 is
indicated as add-on treatment for asthma in patients with
mild to moderate persistent asthma, when they remain
inadequately controlled by inhaled corticosteroids associ-
ated or not to short-acting beta-2 adrenergic agonists. To
date, there is no indication in this age group to prescribed
MTL-4 as controller in monotherapy.
Study population
We selected infants:
 Considered to be asthmatic, i.e. receiving ≥ 2
consecutive dispensations of any respiratory drug
(R03 ATC classification), from March 8, 2010
(launch of MTL-4 in France). The second R03
medication had to be dispensed between 8 and
91 days after the first. Infants had to be aged 6 to
24 months at dispensation of the first R03 drug.
 Presenting uncontrolled asthma, identified from
exacerbation (i.e. asthma-related hospitalizations
ICD-10 codes J45 or J46, or dispensation of oral
corticosteroids), or acute loss of asthma control
(i.e. addition of short-acting beta agonists to
existing respiratory therapy, switch to higher dose
ICS therapy, or switch to nebulized CS), within
6 months following the first R03 dispensation. For
all patients, the date of exacerbation or marker of
acute loss of control was defined as the index date.
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Figure 1 General study design.
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Infants initiating a treatment with ICS monotherapy
were compared to those having MTL-4 (with or without
concomitant ICS therapy).
MTL-4 and ICS groups were defined at index date:
– MTL-4 group: infants receiving a dispensation of
MTL-4 within 7 days after the index date with or
without concomitant ICS therapy,
– ICS group: infants not receiving MTL-4 within
7 days after the index date, nor in the 3 months be-
fore the index date. ICS was investigated only when
dispensed in monotherapy (i.e. no fixed dose
combinations).Table 1 Characteristics of infants (N = 1,149)
Number Percentage
Males 733 63.8%
Age (mean, months) 14.1 (SD = 5.6)Study outcomes
The outcome was the rate of infants with uncontrolled
asthma, defined as above.Any Long-Term Disease status* 47 4.1%
Long-Term Disease status n°14** 9 0.8%
Free-access-to-care status*** 250 21.8%
*Long-term disease status enables patients suffering from a severe chronic
disease, in need of expensive chronic therapy, not to pay in advance for treatments
dispensed in pharmacies and to be fully reimbursed.
**Severe chronic respiratory failure.
***Free-access-to-care status enables patients with socioeconomic difficulties
to receive free medical care.Statistical analyses
Included infants were described, and profiles were
identified according to dispensed therapy (type of R03,
and number of dispensations).
To ensure comparability of both groups, each infant
from the MTL-4 group was matched with one or more
infants from the ICS group, using the following criteria: Age at index date (+/− 3 months)
 Gender
 Number of R03 drugs before index date
 Quarter of index date
We performed two computations of the number of
subjects needed to show specific decreases in uncon-
trolled asthma rates under MTL-4 compared to ICS
(Table 1). For instance, to show a 12% relative decrease
of uncontrolled asthma under MTL-4 [15], with a power
of 90%, we needed at least 4,210 infants in each group, i.e.
at least 42 infants in the MTL-4 group of this pilot study.
All analyses were performed using SAS software,
version 9.3 (SAS Institute Inc., Cary, NC, USA).
With 2 dispensations of respiratory 
medications (R03) between March 8, 2010 
and March 15, 2012
1 790
With uncontrolled asthma
With 6 months follow-up
1 614 (90%)
1 149 (71%)
176 excluded due to lack of
uncontrolled asthma during the
required time-interval
465 infants with < 6 months
follow-up
Figure 2 Patients’ selection.
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Identification of infants with asthma
In the EGB, we identified 1,790 infants meeting our
definition of asthma (Figure 2).
Of these, 1,614 (90%) had uncontrolled asthma, accord-
ing to our definition; 465 (26%) were not included due to
limited duration of follow-up (less than 6 months after
index date). Thus, our final sample included 1,149 infants
with uncontrolled asthma.
The sample included a majority of boys (63.8%)
(Table 1). Mean age was 14.1 months (SD = 5.6); 4.1% of
infants benefited from LTD status, while 21.8% had free-
access-to-care status.
Frequency of exposure to MTL-4 and ICS
Of all infants meeting inclusion criteria, 51 (4.4%) and 768
(66.8%) were assigned to MTL-4 and ICS groups, respectively.
Identification of outcomes (exacerbations and/or acute
loss of asthma control)
After index date, uncontrolled asthma occurred in
78.8% of infants in the MTL-4 group and 78.4% of theTable 2 Markers of uncontrolled asthma during 6-month
follow-up (MTL-4 group, n = 51 and ICS group, n = 768)







Dispensation of oral corticosteroids 25 (49.0%) 470 (61.2%)
Asthma-related hospitalizations 2 (3.9%) 37 (4.8%)
Markers of acute loss of asthma control** 31 (60.8%) 445 (57.9%)
Any of the above 40 (78.4%) 605 (78.8%)
*Not mutually exclusive; an infant could have one or more markers of
exacerbation during the period.
**Addition of short-acting beta agonists to existing respiratory therapy, switch
to higher dose ICS therapy, or switch to nebulized CS.ICS group. Oral corticosteroids were dispensed to 49%
of the MTL-4 group and 61% of the ICS group,
hospitalizations for asthma were identified in 3.9% and
4.8%, respectively, and acute loss of control occurred in
60.8% and 57.9%, respectively (Table 2).
Feasibility of matching, according to predefined criteria
For age, gender and quarter of index date, the distribu-
tion of the matching criteria in the two groups are
described in Table 3, supporting the feasibility of
matching according to these criteria.
Due to the limited number of R03 dispensations
before index date (data not shown), and in agreement
with the study Scientific Committee, the criterion
“number of R03 before index date” was replaced with
“pre-inclusion therapeutic typologies”, that was defined
as follows:
 No specific treatment for asthma, or oral
corticosteroids
 Reliever therapy only












Female: n (%) 14 (27.5%) 286 (37.2%) 300 (36.6%)
Quarter of index
date:
Q1 2010-2011 9 (17.6%) 245 (31.9%) 254 (31.0%)
Q2 2010-2011 20 (39.2%) 221 (28.8%) 241 (29.4%)
Q3 2010-2011 10 (19.7%) 106 (13.8%) 116 (14.2%)
Q4 2010-2011 12 (23.5%) 196 (25.5%) 208 (25.4%)
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This pilot study was performed using the EGB database,
a 1/97 sample of the whole French population, to pre-
pare a project aimed at assessing the effectiveness of
MTL-4 in infants suffering from asthma. The first three
questions addressed by this pilot study were answered
satisfactorily, i.e. identification of infants with uncontrolled
asthma (N = 1,149), frequency of exposure to MTL-4 and
ICS (n = 51 and 768, respectively), and occurrence of out-
comes (78% and 79% of MTL-4 and ICS infants, respect-
ively). For the last question, i.e. development of matching
criteria, we defined a new marker of severity (therapeutic
typologies).
Asthma in infants under 36 months is usually defined
as an episode of wheezing dyspnea that has occurred at
least 3 times since birth [2]. In our study, as diagnoses
are usually missing in French claims data, the identification
of asthmatic infants relied on a proxy, i.e. the use of specific
therapy (2 consecutive dispensations of respiratory drugs
ATC R03, separated by an interval of 8 to 91 days). Based
on this approach, 1,790 asthmatic infants were identified
between March 2010 and March 2012. Combined with
the mean annual number of births in France – around
790,000 –, the prevalence of asthma may be estimated to
be around 11% in infants. Epidemiological data on the
prevalence of asthma in infants are rare. One report sug-
gests that the prevalence of these symptoms at the age of
two lies between 11.9% and 26.6% [16], which is compat-
ible with our results. The sex ratio observed in our study
is consistent with data available for young children under
5 years, where a 2/1 ratio is traditionally observed in favor
of boys [17]. In summary, prevalence and sex-ratio sup-
port the validity of the algorithm used for the identifica-
tion of infants with asthma in our study.
Using our selection criteria, 51 users of MTL-4 were
identified in the EGB, together with 768 users of ICS.
These represent adequate counts to meet the objectives
of the final study, in particular for group comparison.
Sales data suggest that a maximum of 78,000 infants
aged 6 to 24 months were exposed to MTL-4 over a 3-
year period (2010 to 2012), which corresponds to around
250 infants/year in the EGB, in line with our figures
stemming from strict inclusion criteria [18]. Similarly,
the identification of outcomes in the EGB and their
frequency also confirmed that the study was feasible
using claims data (≥49% of infants in the MTL-4 and
≥57.9% of the ICS groups were identified with uncon-
trolled asthma, or dispensing of oral corticosteroids).
According to the IRDES (Institut de Recherche et Docu-
mentation en Economie de la Santé, the national health
economics research institute) survey [17], in 60% of
patients, asthma is inadequately controlled (based on
GINA criteria). According to stricter criteria from the
French health authority (Haute Autorité de Santé, HAS)guidelines [2], asthma is inadequately controlled in
83% of patients. In the Er’Asthme study [19,20] that
investigated children aged 6 to 14 years, considering
the Canadian criteria which were similar to HAS criteria,
asthma was inadequately controlled in 73% of children.
The results obtained in our explanatory study are not
incompatible with these references, again supporting
their validity.
This pilot study was conducted using the EGB data-
base [14], which is a sample of French national claims
data. In several countries, comparative effectiveness re-
search studies have been conducted in asthma using
claims data [21,22]. In France, our study was among the
firsts with this objective, justifying a feasibility study. A
major advantage of EGB is to record exhaustive medical
resource utilization in a 1/97th sample of the 86% of
French population covered by the national health insurance
system. In addition to detailed data on drug utilization, the
EGB also contains data on all medical procedures, and all
medical and paramedical visits. Information on prescribers
is also available. The linkage of primary care with hospital
data (PMSI) provides access to data on hospitalizations
(private and public hospitals), i.e. exhaustive individual
medical resource utilization. As the SNIIR-AM records
health care provided to infants following exposure to MTL-
4, it was a priori considered to be a useful source of data to
test the effectiveness of this drug. Another approach would
have been a field study in a population of asthmatic infants.
Besides practical pitfalls, such as complex organization and
long timelines, a field study would have been exposed to re-
call bias, particularly on past medical resource utilization.
Nonetheless, the EGB database has certain intrinsic
limitations. Few variables were available to describe pa-
tients: age, gender, free-access-to-care status, and LTD
status in case of more severe disease. EGB does not in-
clude clinical data (e.g. lab test results), or information
on family history. Prescriptions without dispensations or
dispensations without drug utilization by the patient are
not recorded, neither are prescribed doses or durations
of prescriptions [23].
This study had other limitations. Uncontrolled asth-
matic infants were identified using ≥2 distinct R03 drug
dispensations followed by exacerbation and/or acute loss
of control. These criteria excluded a significant propor-
tion of MTL-4 -exposed infants. This also limited the
generalizability of our findings. For example, the rate of
outcomes during the 6 months of follow-up could have
been overestimated by the choice of the selection criteria,
as asthma had to be uncontrolled for infants to be in-
cluded. Also, defining exacerbations from dispensations of
oral corticosteroids could be criticized as such use could
be due to conditions other than asthma. However, it is
likely that requiring the initial dispensation of oral cortico-
steroids to be followed within seven days by a dispensation
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marker to identify asthma exacerbations.
Finally, the matching for asthma severity was based on
proxies (therapeutic typologies and past asthma-related
hospitalization) and probably did not fully account for
potential differences in severity between the two groups.
Therapeutic typologies allowed us to classify infants into
three groups of severity based on treatments before
index date: infants with no asthma treatment, infants
with only reliever therapy, and infants already receiving
controller therapy. We believe that this classification
optimized the use of information available in French
claims data.
Importantly, the study design was based on the as-
sumption that uncontrolled asthma leads to increased
medical resource utilization, and this concept is now
generally accepted, as exemplified by recent definitions
[2,24]. Other methodological biases are, however, possible.
As in any observational study comparing effectiveness
between two therapeutic strategies, indication bias can
never be excluded [25]; nonetheless, as already stressed,
matching of infants on the typology of initial therapy
limits this bias.
Conclusions
Our findings support the feasibility of a final SNIIR-AM
project for the identification of asthmatic infants, their
outcomes, and matching criteria; this allowed us to
finalize the SNIIR-AM protocol. In addition, this study
confirmed that, with appropriate methodology and by
using valid criteria, French claims data are an adequate
resource to conduct comparative effectiveness studies in
asthma and could be a practical alternative to field studies.
From national claims data, the prevalence of asthma in
France was estimated to be around 11% in infants. Finally,
the algorithm used to identify infants with asthma could
be applied to other studies using claims data.
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